INSIGHTS

In this section, we are regularly sharing relevant information on patient-focused drug development.

Patient preferences as input to drug development
Laura Lassen
Posted by Laura Lassen
December 4, 2020

Patient preferences as input to medical product decision making

PREFER’s patient input to decision making under evaluation by EMA and EUnetHTA. At Clinigma®, we are always happy to follow the development of projects promoting patient engagement...

Read More
Feedback from investigators and study nurses
Laura Lassen
Posted by Laura Lassen
November 27, 2020

Have you considered improving the feedback from investigators and study nurses in your clinical trials?

The importance of interviewing investigators and study nurses. Not only is it relevant to interview the patients participating in clinical trials – it can also be highly valuable to…

Read More
The benefits of interviewing patients
Laura Lassen
Posted by Laura Lassen
November 20, 2020

The benefits of interviewing patients when developing orphan drugs

Screening and exit interviews are particularly beneficial to inform the development of drugs for rare diseases. Patient interviews can be helpful to obtain direct patient feedback regarding…

Read More
Inform your outcomes strategy by listening to the trial patients
Laura Lassen
Posted by Laura Lassen
November 6, 2020

Can you set a strong outcomes strategy without listening to the patients?

Interviewing patients can help you in choosing the most relevant patient-reported outcome measures to apply in your clinical trials. Patient-reported outcome measures (PROMs) are frequently applied…

Read More
Get to know what the users think about your investigational drug
Laura Lassen
Posted by Laura Lassen
October 30, 2020

Can you set a strong marketing strategy without hearing what users think about your investigational drug?

Get a clearer picture of your investigational drug prior to market launch. Interestingly, the pharmaceutical industry has remained one of the few industries where direct user feedback is not…

Read More
Collaboration to reinforce patient relevance in evidence generation
Laura Lassen
Posted by Laura Lassen
October 23, 2020

EMA wants to strengthen the collaboration with HTAs to reinforce patient relevance in evidence generation

Highlights on EMA’s focus to advance patient-centred access to medicines in partnership with healthcare systems. In EMA’s Regulatory Science Strategy to 2025, the EMA presents...

Read More